Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: FOLFIRI
Drug: mFOLFOX6

First Posted Date: 2022-12-02

Last Posted Date: 2022-12-02

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT05634590

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Fruquintinib
Drug: Sintilimab

First Posted Date: 2022-11-23

Last Posted Date: 2022-11-23

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 29

Registration Number: NCT05625737

Locations: 🇨🇳
Wuhan Union Hospital, China, Wuhan, Hubei, China

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Phase 2

Recruiting

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: fruquintinib+sintilimab
Drug: axitinib / everolimus
Drug: fruquintinib

First Posted Date: 2022-08-30

Last Posted Date: 2024-03-28

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 264

Registration Number: NCT05522231

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: HAIC

First Posted Date: 2022-08-22

Last Posted Date: 2022-08-22

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05511051

Locations: 🇨🇳
People's Hospital of Inner Mongolia, Hohhot, China
🇨🇳
Dalian Medial University Affiliated Second Hospital, Dalian, China
🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2022-07-07

Last Posted Date: 2022-07-07

Lead Sponsor: Weijian Guo

Target Recruit Count: 134

Registration Number: NCT05447715

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Procedure: HAIC
Drug: Fruquintinib
Drug: Tislelizumab
Drug: Raltitrexed
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2022-06-28

Last Posted Date: 2024-01-17

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT05435313

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Phase 2

Recruiting

Conditions: Advanced Colorectal Carcinoma
Liver Metastasis Colon Cancer

Interventions: Drug: Fruquintinib
Procedure: Hepatic Arterial Infusion Chemotherapy

First Posted Date: 2022-06-06

Last Posted Date: 2022-06-06

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 27

Registration Number: NCT05406206

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Fruquintinib DDI Study With P-gp and BCRP Substrates

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Rosuvastatin
Drug: Dabigatran Etexilate

First Posted Date: 2022-05-10

Last Posted Date: 2022-10-06

Lead Sponsor: Hutchmed

Target Recruit Count: 32

Registration Number: NCT05368805

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Phase 2

Conditions: Colorectal Neoplasms

Interventions: Radiation: hypofractionation Radiotherapy
Drug: sintilimab
Drug: GM-CSF
Drug: Fruquintinib

First Posted Date: 2022-03-23

Last Posted Date: 2022-03-31

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 71

Registration Number: NCT05292417

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Carcinoma

Interventions: Drug: Fruquintinib

First Posted Date: 2022-02-25

Last Posted Date: 2022-02-25

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT05257122

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy